ArticlePloS one2026
Minigenes for heterologous expression of human and mouse cationic trypsinogen.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inborn mutations in the PRSS1 gene encoding human cationic trypsinogen cause hereditary pancreatitis. In mouse models, PRSS1 mutations are often studied in the context of the Prss3b gene that codes for mouse cationic trypsinogen. To characterize the cellular and biochemical effects of trypsinogen mutations, heterologous expression in transfected cell lines is often employed. Recent studies with the human and mouse trypsin inhibitor SPINK1 indicated that minigene expression constructs carrying a short intron yield markedly higher recombinant protein levels than cDNA constructs. Here, we investigated whether the minigene approach would increase the expression of human and mouse cationic trypsinogen in transfected HEK 293T cells. We found that compared with the cDNA, minigene constructs increased PRSS1 and Prss3b mRNA levels by 2.5-fold and 4.5-fold on average, respectively. Surprisingly, however, the amount of secreted human cationic trypsinogen remained unchanged while secretion of mouse cationic trypsinogen was increased 2.9-fold. The observations indicate that minigene expression constructs are effective in boosting mRNA levels in transfected cells, however, this may not always translate to elevated protein secretion. In these cases, inefficient protein translation and/or folding may be rate limiting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.